I hereby certify that, on the date shown below, this correspondence is being:
deposited with the United States Postal Service in an envelope addressed to:
Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450,
under 37CFR § 1.8(a), with sufficient postage as first class mail, or
under 37CFR § 1.10, as "Express Mail Post Office to Addressee" Mailing Label No.

transmitted by facsimile to the Patent and Trademark Office, Fax Number_______,

Atty. Docket No. AR02164USACON1

CN 27777

Date: <u>Feb. 10</u>, 2004 By: Lois F. Miller

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s):

David E. EDGREN et al.

Serial No.:

10/696,370

Filed:

October 28, 2003

For:

ANTIDEPRESSANT DOSAGE

FORM

Group Art Unit: to be assigned

Examiner: to be assigned

INFORMATION DISCLOSURE

STATEMENT

Honorable Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified national application (other than a continued prosecution application under §1.53(d)), within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the

mailing date of	f a first (Office Action on th	e merits of the abov	ve-identified a	pplica	tion, or before the
mailing date of	f a first (Office Action after	the filing of a reque	est for continue	ed exa	amination under
§1.114, no add	ditional f	ee is required.				
			9(a), this Information			ment is being filed
in connection v	with 🔲 1	the first or ⊡seco	nd After Final Subn	nission, therefo	ore:	
		Statement in Acco	ordance with §1.97	(e) (attached);	or	
		Please charge De as set forth in §1.	eposit Account No. 17(p).	10-0750/	1	the fee of <u>\$180.00</u>
	In acco	ordance with §1.97	(c), this Information	n Disclosure S	tatem	ent is being filed
after the period	d set for	th in §1.97(b) abo	ve but before the m	nailing date of	either	a Final Action
under §1.113	or a Not	ice of Allowance u	nder §1.311, or an	action that oth	nerwis	e closes
prosecution ar	nd that it	is accompanied b	y one of:			
		Statement in Acco	ordance with §1.97	(e) (attached);	or	
		Please charge De	eposit Account No.	10-0750/	1	the fee of <u>\$180.00</u>
		as set forth in	§1.17(p).			
	In acco	ordance with §1.97	(d), this Information	n Disclosure S	tatem	ent is being filed
after the mailir	ng date	of either a Final Ad	ction under §1.113	or a Notice of	Allowa	ance under
§1.311 but bet	fore the	payment of the Iss	sue Fee. Applicant	(s) hereby pet	ition(s) for consideration
of this Informa	tion Dis	closure Statement	. Included are: Sta	atement in Acc	cordar	nce with §1.97(e)
as set forth be	low and	the fee of <u>\$180.00</u>	0 as set forth in §1.	17(p).		
	Copies	of each of the ref	erences listed on th	e attached Fo	rm P1	rO-1449 are
enclosed here	with.					
[]	•	of references liste	ed on the attached I	Form PTO-144	49 are	enclosed herewith
EXCEPT THA	.1.					
			uminous nature of researces are a	_		

USSN: 10/696,370, filed October 28, 2003 AR02164USACON1 Information Disclosure Statement

	If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.
publication liston application wa	Copies of only foreign patent documents and non-patent literature are enclosed in th 37 CFR 1.98 (a)(2). (The U.S. patents and each U.S. patent application ed on the attached Form PTO-1449 are not enclosed because this U.S. patent is filed after June 30, 2003 or this international application has entered the national S USC §371 after June 30, 2003 (see USPTO waiver of requirement under 37 CFR
\boxtimes	There are no listed references which are not in the English language.
as follows:	The relevance of those listed references which are not in the English language is
⊠ which are liste	Attached are copies of search report(s) from corresponding patent application(s), d on the attached Submission Under MPEP 609 D.
D be deemed rel	Attached are the following non-published pending patent applications which may evant, which are listed on the attached Submission Under MPEP 609 D.
Please	charge any deficiency or credit any overpayment to Deposit Account No. 10-0750.
	Respectfully submitted, Attorney for Applicants

USSN: 10/696,370, filed October 28, 2003 AR02164USACON1 Information Disclosure Statement

One Johnson & Johnson Plaza, WH3221

ALZA CORPORATION c/o Johnson & Johnson

New Brunswick, NJ 08933 Customer No.: 27777 Samuel E. Webb, Reg. No.: 44,394

Tel. No.: 650-564-2024

Fax. No. 650-564-2195

FEB 1 9 2004 W

PTO-SB-08A (08-00) Approved for use through 10-31-2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A-PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 1 of 3

a collection of information unless it displays a	a valid OMB control number.
Application Number	10/696,370
Filing Date	October 28, 2003
First Named Inventor	David E. EDGREN
Group Art Unit	Not yet assigned
Examiner Name	Not yet assigned
Attorney Docket Number	AR02164USACON1

	DATELIT	D001	10 SELITO
11.5	PATENT	DOGL	IMENIS

		U.S. Patent Documer	ıt	U.S. PATENT DOCUMENTS		
Examiner Initials			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear	
	AA	2,799,241		Wurster	07/16/1957	
	AB	3,133,132		Loeb et al.	05/12/1964	
	AC	3,173,876		Zobrist	03/16/1965	
	AD	3,276,586		Rosaen	10/04/1966	
	AE	3,541,005		Strathmann et al.	11/17/1970	
	AF	3,541,006		Bixler et al.	11/17/1970	
	AG	3,546,142		Michaels et al.	12/08/1970	
	АН	3,589,122		Zaffaroni	08/10/1971	
	Al	3,589,123		Zaffaroni	08/10/1971	
	AJ	3,845,770		Theeuwes et al.	11/05/1974	,
	AK	3,916,899		Theeuwes et al.	11/04/1975	
	AL	4,063,064		Saunders et al.	12/13/1977	
	AM	4,088,864		Theeuwes et al.	05/09/1978	
	AN	4,111,201		Theeuwes et al.	09/05/1978	
	AO	4,160,020		Ayer et al.	07/03/1979	
	AP	4,200,098		Ayer et al.	04/29/1980	
	AQ	4,285,987		Ayer et al.	08/25/1981	
	AR	4,327,725	_	Cortese et al.	05/04/1982	
	AS	4,535,189		Husbands et al.	08/13/1985	
	AT	4,611,078		Husbands et al.	09/09/1986	
	AU	4,612,008		Wong et al.	09/16/1986	
	AV	4,761,501		Husbands et al.	08/02/1988	

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

FEB 1 9 2004 Diluci vic : apon....

PTO-SB-08A (08-00) Approved for use through 10-31-2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 2 of 3

Traile Citib Cone of Hambon.
10/696,370
October 28, 2003
David E. EDGREN
Not yet assigned
Not yet assigned
AR02164USAC ON1

U.S. PATENT DOCUMENTS

		U.S. Patent Docum	ent			
Examiner Initials	Cite No.1	Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear
	AW	4,765,989		Wong et al.	08/23/1988	
_	AX	4,783,337		Wong et al.	11/08/1988	
	AY	4,842,867		Ayer et al.	06/27/1989	
	AZ	4,863,744		Urquhart et al.	09/05/1989	
	ВА	4,946,687		Ayer et al.	08/07/1990	
	ВВ	4,948,592		Ayer et al.	08/14/1990	
	ВС	4,950,486		Ayer et al.	08/21/1990	
	BD	4,966,769		Guittard et al.	10/30/1990	
	BE	5,190,765		Jao et al.	03/02/1993	
	BF	6,440,457	B1	Edgren et al.	08/27/2002	

FOREIGN PATENT DOCUMENTS

				<u> </u>	CLIGHT ATENT DOCUMENTS			
		Foreign	Patent Document		Name of Patentee or	Date of Publication of Cited Document	Pages, Columns, Lines, where relevant	
Examiner Initials	Cite No.¹	. 0003 N 4 10101.5		dCode⁵	Applicant of Cited Document	mm-dd-yyyy	passages or relevant figures appear	T⁵
	BG	EP	0 112 669	A2	American Home Products	07/04/1984		

Examiner	Date
Signature	Considered

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

PTO-SB-08A (08-00) Approved for use through 10-31-2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to

Under the Paperwork Paperw INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 3 of 3

a collection of information unless it displays a	a collection of information unless it displays a valid OMB control number.					
Application Number	10/696,370					
Filing Date	October 28, 2003					
First Named Inventor	David E. EDGREN					
Group Art Unit	Not yet assigned					
Examiner Name	Not yet assigned					
Attorney Docket Number	AR02164USACON1					

	<u> </u>	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner's Initials*	Cite No.1	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and-or country where published	T ²
	ВН	Louis F. Fabre & H. Paul Putman, "An ascending single-dose tolerance study of WY-45,030, A bicyclic antidepressant, in healthy men," <u>Current Therapeutic Research</u> , 42(5):901-909, November 1987.	
	ВІ	Alvin Felmeister, "Powders," Remington's Pharmaceutical Sciences, 14th Edition, Ch 86 & 87, pp. 1626-1648, Mack Publishing Co., 1970.	
	BJ	Goodman & Gilman, <u>The Pharmacological Basis of Therapeutics</u> , 4 th Ed., Page 182, Macmillan Publishing Co., New York, 1970.	
	вк	Goodman & Gilman, <u>The Pharmacological Basis of Therapeutics</u> , 7 th Ed., Page 7, Macmillan Publishing Co., New York, 1985.	
	BL	Goodman & Gilman, <u>The Pharmacological Basis of Therapeutics</u> , 8th Ed., Pages 407 & 411, Pergamon Press, New York, 1990.	
	вм	P. Grafton, "General principles for designing with plastics," <u>Modern Plastics Encyclopedia</u> , 46:62-71, 1969.	
	BN	Robert E. King, "Tablets, Capsules, and Pills," Remington's Pharmaceutical Sciences, 14th Edition, Ch. 87, pp. 1649-1680, Mack Publishing Co., 1970.	
	во	Mark A. Longer & Joseph R. Robinson, "Sustained-Release Drug Delivery Systems," Remington's Pharmaceutical Sciences, 18th Edition, Ch 91, pp. 1676-1686, Mack Publishing Co., 1990.	
	ВР	The Merck Index, 11 Ed., page 1365 & MISC-107, 1989. "Sodium Nitrate"	
	BQ	The Merck Index Online, Merck & Co. 1996, 1997. "10079 Monograph Name: Venlafaxine"	
	BR	Scott & Roff, Handbook of Common Polymers, CRC Press., Cleveland Ohio, 1971.	
	BS	Dale E. Wurster, "Air-Suspension Technique of Coating Drug Particles", <u>J. Am. Pharm. Assoc</u> , 48(8):451-454, August 1959	
	вт	Dale E. Wurster, "Preparation of Compressed Tablet Granulations by the Air-Suspension Technique II", <u>J. Am. Pharm. Assoc</u> , 49(2):82-84, February 1960.	_

Examiner		Date	
Signature		Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

¹ Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. s Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.



SUBMISSION UNDER MPEP 609 D

Application Number	10/696,370 October 28, 2003		
Filing Date			
First Named Inventor	David E. EDGREN		
Group Art Unit	To be assigned		
Examiner Name	To be assigned		
Attorney Docket Number	AR02164USACON1		

Page 1 of 1

U.S. PATENT DOCUMENTS								
			U.S. Patent Document					
Examiner Initials	Cite No.1	Name of Patentee or Applicant of Cited Document	Number	Kind Code ² (if known)	Pages, Columns, Lines, where relevant passages or relevant figures appear			

FOREIGN PATENT DOCUMENTS Foreign Patent Document Pages, Columns, Lines, where relevant passages Name of Patentee or Examiner or relevant figures Applicant of Cited Document KindCode⁵ Office³ Number⁴ appear No.1 OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), T² Cite No.¹ Examiner title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published Initials* International Search Report dated November 30, 1994, for corresponding Appln No. PCT/US94/06049.

		_
Examiner	Date	
Signature	Considered	